Valuation: LivaNova PLC

Market Cap 4.43B 3.87B 3.57B 3.3B 6.21B 427B 6.35B 42.73B 16.81B 209B 16.65B 16.28B 720B P/E 2026 *
28.9x
P/E 2027 * 25.1x
Enterprise Value 4.46B 3.89B 3.59B 3.31B 6.24B 429B 6.38B 42.94B 16.89B 210B 16.73B 16.36B 723B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.64x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.43B
+1.87%+7.19%-18.59%-6.15% 175B
-0.43%-0.80%-7.15%-3.39% 106B
-0.03%+1.47%+5.13%+60.41% 59.91B
+0.66%+0.96%+37.64%+54.22% 51.95B
-1.10%+4.10%-11.56%-37.95% 43.58B
-3.21%-3.05% - - 33.65B
-1.71%+2.25%-8.63%-42.64% 29.58B
-1.16%+1.28%+69.87%-7.10% 25.31B
-1.49%+0.85%-3.43%-4.22% 21.23B
Average -0.66%+1.58%+7.91%+1.65% 60.79B
Weighted average by Cap. +0.09%+2.75%-1.60%+3.53%

Financials

2026 *2027 *
Net sales 1.51B 1.32B 1.22B 1.12B 2.11B 145B 2.16B 14.54B 5.72B 71.12B 5.66B 5.54B 245B 1.61B 1.41B 1.3B 1.2B 2.26B 155B 2.31B 15.56B 6.12B 76.14B 6.06B 5.93B 262B
Net income 148M 130M 120M 110M 208M 14.29B 213M 1.43B 563M 7B 557M 545M 24.09B 179M 157M 145M 133M 251M 17.28B 257M 1.73B 680M 8.46B 674M 659M 29.14B
Net Debt 22.09M 19.3M 17.81M 16.42M 30.95M 2.13B 31.64M 213M 83.75M 1.04B 82.96M 81.14M 3.59B -165M -144M -133M -122M -231M -15.84B -236M -1.59B -624M -7.76B -618M -604M -26.71B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA